Kenneth J. Smith, MD, MS

home / authors / kenneth-j-smith-md-ms

Articles

September 19th 2013

FDA Warning and Removal of Rosiglitazone From VA National Formulary

Sherrie L. Aspinall, PharmD, MSc Xinhua Zhao, PhD Chester B. Good, MD, MPH Roslyn A. Stone, PhD Kenneth J. Smith, MD, MS Francesca E. Cunningham, PharmD

After the FDA warning and removal of rosiglitazone from the VA National Formulary, glucose control may have declined among those discontinuing rosiglitazone without receiving replacement medication.

February 11th 2013

Cost-Effectiveness of Medicare Drug Plans in Schizophrenia and Bipolar Disorder

Kenneth J. Smith, MD, MS Seo Hyon Baik, PhD Charles F. Reynolds III, MD Bruce L. Rollman, MD, MPH Yuting Zhang, PhD

In Medicare Part D, generic drug coverage was cost saving compared with no coverage in bipolar disorder and schizophrenia while improving health outcomes.

March 7th 2012

Optimal Approach to Improving Trauma Triage Decisions: A Cost-Effectiveness Analysis

Deepika Mohan, MD, MPH Amber E. Barnato, MD, MPH, MS Matthew R. Rosengart, MD, MPH Derek C. Angus, MD, MPH, FRCP Kenneth J. Smith, MD, MS

To set priorities for quality improvement in trauma triage, we compared the cost-effectiveness of current practice with interventions to improve physician adherence to clinical guidelines.

March 10th 2011

Economic Model for Emergency Use Authorization of Intravenous Peramivir

Bruce Y. Lee, MD, MBA Julie H. Y. Tai, MD Rachel R. Bailey, MPH Sarah M. McGlone, MPH Ann E. Wiringa, MPH Shanta M. Zimmer, MD Kenneth J. Smith, MD, MS Richard K. Zimmerman, MD, MPH

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

January 14th 2011

Economic Model for Emergency Use Authorization of Intravenous Peramivir

Bruce Y. Lee, MD, MBA Julie H. Y. Tai, MD Rachel R. Bailey, MPH Sarah M. McGlone, MPH Ann E. Wiringa, MPH Shanta M. Zimmer, MD Kenneth J. Smith, MD, MS Richard K. Zimmerman, MD, MPH

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

July 13th 2010

Screening Cardiac Surgery Patients for MRSA: An Economic Computer Model

Bruce Y. Lee, MD, MBA Ann E. Wiringa, MPH Rachel R. Bailey, MPH Vishal Goyal, MPH G. Jonathan Lewis, DO, MPH Becky Y. K. Tsui, MPH Kenneth J. Smith, MD, MS Robert R. Muder, MD

Routine preoperative MRSA screening of cardiac surgery patients could provide substantial economic value to third-party payers and hospitals under a wide range of circumstances.

March 9th 2010

Cost-Effectiveness of Pneumococcal Polysaccharide Vaccine Among Healthcare Workers During an Influenza Pandemic

Kenneth J. Smith, MD, MS Mahlon Raymund, PhD Mary Patricia Nowalk, PhD, RD Mark S. Roberts, MD, MPP Richard K. Zimmerman, MD, MPH

Pneumococcal polysaccharide vaccination of healthcare workers during an influenza pandemic is cost-effective from a societal perspective but not from a hospital perspective without external subsidy.

March 1st 2010

Economics of Influenza Vaccine Administration Timing for Children

Bruce Y. Lee, MD, MBA Julie H. Y. Tai, MD Rachel R. Bailey, MPH Kenneth J. Smith, MD, MS Andrew J. Nowalk, MD, PhD

Vaccinating children earlier (ie, September or October) can provide net economic benefit to society and to third-party payers. Vaccination of children remained cost-effective through December.